Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Price, Quote, News and Overview

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

59.97  -0.11 (-0.18%)

After market: 59.97 0 (0%)

HALO Quote, Performance and Key Statistics

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (7/31/2025, 8:00:02 PM)

After market: 59.97 0 (0%)

59.97

-0.11 (-0.18%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High70.51
52 Week Low42.01
Market Cap7.39B
Shares123.22M
Float121.85M
Yearly DividendN/A
Dividend YieldN/A
PE13.18
Fwd PE7.85
Earnings (Next)08-05 2025-08-05/amc
IPO01-30 2003-01-30


HALO short term performance overview.The bars show the price performance of HALO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 4 6 8 10

HALO long term performance overview.The bars show the price performance of HALO in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of HALO is 59.97 USD. In the past month the price increased by 11.39%. In the past year, price increased by 10.87%.

HALOZYME THERAPEUTICS INC / HALO Daily stock chart

HALO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.41 333.88B
AMGN AMGEN INC 14.21 158.68B
GILD GILEAD SCIENCES INC 14.51 139.68B
VRTX VERTEX PHARMACEUTICALS INC N/A 117.32B
REGN REGENERON PHARMACEUTICALS 12.31 58.89B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 51.14B
ARGX ARGENX SE - ADR 116.78 41.02B
ONC BEONE MEDICINES LTD-ADR 7.71 32.59B
BNTX BIONTECH SE-ADR N/A 25.84B
INSM INSMED INC N/A 20.35B
SMMT SUMMIT THERAPEUTICS INC N/A 19.58B
BIIB BIOGEN INC 8.09 18.76B

About HALO

Company Profile

HALO logo image Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 350 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Company Info

HALOZYME THERAPEUTICS INC

12390 El Camino Real

San Diego CALIFORNIA 92121-1345 US

CEO: Helen I. Torley

Employees: 350

HALO Company Website

HALO Investor Relations

Phone: 18587948889

HALOZYME THERAPEUTICS INC / HALO FAQ

What is the stock price of HALOZYME THERAPEUTICS INC today?

The current stock price of HALO is 59.97 USD. The price decreased by -0.18% in the last trading session.


What is the ticker symbol for HALOZYME THERAPEUTICS INC stock?

The exchange symbol of HALOZYME THERAPEUTICS INC is HALO and it is listed on the Nasdaq exchange.


On which exchange is HALO stock listed?

HALO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HALOZYME THERAPEUTICS INC stock?

15 analysts have analysed HALO and the average price target is 67.96 USD. This implies a price increase of 13.32% is expected in the next year compared to the current price of 59.97. Check the HALOZYME THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HALOZYME THERAPEUTICS INC worth?

HALOZYME THERAPEUTICS INC (HALO) has a market capitalization of 7.39B USD. This makes HALO a Mid Cap stock.


How many employees does HALOZYME THERAPEUTICS INC have?

HALOZYME THERAPEUTICS INC (HALO) currently has 350 employees.


What are the support and resistance levels for HALOZYME THERAPEUTICS INC (HALO) stock?

HALOZYME THERAPEUTICS INC (HALO) has a support level at 58.23 and a resistance level at 60.09. Check the full technical report for a detailed analysis of HALO support and resistance levels.


Is HALOZYME THERAPEUTICS INC (HALO) expected to grow?

The Revenue of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 24.54% in the next year. Check the estimates tab for more information on the HALO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HALOZYME THERAPEUTICS INC (HALO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HALOZYME THERAPEUTICS INC (HALO) stock pay dividends?

HALO does not pay a dividend.


When does HALOZYME THERAPEUTICS INC (HALO) report earnings?

HALOZYME THERAPEUTICS INC (HALO) will report earnings on 2025-08-05, after the market close.


What is the Price/Earnings (PE) ratio of HALOZYME THERAPEUTICS INC (HALO)?

The PE ratio for HALOZYME THERAPEUTICS INC (HALO) is 13.18. This is based on the reported non-GAAP earnings per share of 4.55 and the current share price of 59.97 USD. Check the full fundamental report for a full analysis of the valuation metrics for HALO.


What is the Short Interest ratio of HALOZYME THERAPEUTICS INC (HALO) stock?

The outstanding short interest for HALOZYME THERAPEUTICS INC (HALO) is 7.88% of its float. Check the ownership tab for more information on the HALO short interest.


HALO Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to HALO. When comparing the yearly performance of all stocks, HALO turns out to be only a medium performer in the overall market: it outperformed 51.84% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

HALO Fundamental Analysis

ChartMill assigns a fundamental rating of 8 / 10 to HALO. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HALO Financial Highlights

Over the last trailing twelve months HALO reported a non-GAAP Earnings per Share(EPS) of 4.55. The EPS increased by 46.77% compared to the year before.


Industry RankSector Rank
PM (TTM) 44.76%
ROA 22.1%
ROE 100.64%
Debt/Equity 3.13
Chartmill High Growth Momentum
EPS Q2Q%40.51%
Sales Q2Q%35.22%
EPS 1Y (TTM)46.77%
Revenue 1Y (TTM)25.66%

HALO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to HALO. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 32.62% and a revenue growth 24.54% for HALO


Ownership
Inst Owners101.72%
Ins Owners0.82%
Short Float %7.88%
Short Ratio4.4
Analysts
Analysts74.67
Price Target67.96 (13.32%)
EPS Next Y32.62%
Revenue Next Year24.54%